TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01760226
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~* 2+ extranodal sites~* elevated LDH,~* MYC rearrangement OR~* bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6.
Study: NCT01760226
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
Study: NCT01760226
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
Study: NCT00857766
Drug: ADVAIR DISKUS™ 250/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
Study: NCT01988402
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02108704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02555306
Drug: 0.5 mg of DE-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-122 Injectable Solution
Study: NCT02555306
Drug: 1.0 mg of DE-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-122 Injectable Solution
Study: NCT02555306
Drug: 2.0 mg of DE-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-122 Injectable Solution
Study: NCT02555306
Drug: 4.0 mg of DE-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE-122 Injectable Solution
Study: NCT00089791
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by subcutaneous injection
Study: NCT01097811
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg orally q.i.d.
Study: NCT00148122
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
Study: NCT02022670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic sodium nitrite capsules
Study: NCT00879710
Drug: simvastatin or ezetimibe
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
Study: NCT04004325
Drug: FT-4101 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
Study: NCT01065649
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo per oral for 21 days, equal to nortriptyline
Study: NCT02189174
Drug: CLR457
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822120
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822120
Drug: BEACOPP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00822120
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00822120
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01756924
Drug: IV or Oral standard of care antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00051298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00378300
Drug: Oral Probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02540031
Drug: Additional oral preparation (3L of PEG+Asc, Coolprep®)
Normalized name: Digitalis preparation Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study: NCT02540031
Drug: Standard oral preparation (2L of PEG+Asc, Coolprep®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study: NCT01235936
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dose levels
Study: NCT01499849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (4 X 0 mg capsules) 0 mg PO
Study: NCT03736980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% lactose
Study: NCT04633148
Drug: Cyclophosphamide (Non-IMP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion for 3 days
Study: NCT03088800
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Ibuprofen at 10 mg/kg dose
Study: NCT02246075
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01785446
Drug: Effect of dexmedetomidine on cisatracurium and sufentanil consumption
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
Study: NCT01785446
Drug: Consumption of cisatracurium and sufentanil in different age groups.
Approvals — FDA: no, EMA: no, PMDA: no
Description: For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
Study: NCT00291694
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400 mg BID
Study: NCT02950883
Drug: Active Treatment Group 7% Hypertonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline
Study: NCT02950883
Drug: Control Group 0.9% Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline
Study: NCT00343408
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00343408
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02095366
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~* at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~* at 10 minutes and if NPRS\>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~* at 20 minutes and if NPRS\>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
Study: NCT01800305
Drug: Pegylated rhEPO
Normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02707198
Drug: kefir
Normalized name: KEFIRAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ounces of kefir 3 times a day, with or without food.
Study: NCT01189929
Drug: Abraxane®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
Study: NCT02831816
Drug: ZuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT03745170
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study: NCT03745170
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
Study: NCT06455488
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies
Study: NCT02235298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill taken once daily to mimic Dapagliflozin
Study: NCT03565484
Drug: susceptibility guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
Study: NCT03565484
Drug: personal medication history guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
Study: NCT03565484
Drug: salvage treatment for failed eradication
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
Study: NCT02676011
Drug: Atropine mixed with second dose succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
Study: NCT02676011
Drug: Normal saline mixed with second dose succinylcholine
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
Study: NCT02463994
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
Study: NCT05364385
Drug: Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
Study: NCT04447287
Drug: ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04447287
Drug: Placebo ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00912964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching mirabegron placebo tablets.
Study: NCT01302158
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00276601
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00276601
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276601
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01511159
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose by inhalation. Progression to open-label trial part will be based on safety data
Study: NCT02394054
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
Study: NCT02325466
Drug: Aspirin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357916
Drug: PEP005 Topical Gel (0.01% concentration)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02343094
Drug: PBA 7,5g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for 14 days with PBA
Study: NCT02343094
Drug: PBA 15g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for 14 days with PBA
Study: NCT02032836
Drug: lloprost(Ventavis,BAYQ6252, 20 µg/mL)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
Study: NCT02032836
Drug: lloprost(Ventavis,BAYQ6252, 10 µg/mL)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
Study: NCT04196309
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
Study: NCT04501744
Drug: Cohort 1 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
Study: NCT04501744
Drug: Cohort 2 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
Study: NCT04501744
Drug: Cohort 3 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
Study: NCT04501744
Drug: Cohort 4 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
Study: NCT04501744
Drug: Cohort 5 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
Study: NCT04501744
Drug: Cohort 6 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
Study: NCT04501744
Drug: Cohort 7 of M701
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
Study: NCT05249153
Drug: low dose of dexmedetomidine with sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
Study: NCT05249153
Drug: high dose of dexmedetomidine with sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
Study: NCT03871439
Drug: PF-05221304 Formulation A
Normalized name: PF-04360365
DrugBank: Ponezumab (DB15135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg
Study: NCT01792557
Drug: Crystallized phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
Study: NCT00290537
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
Study: NCT01748864
Drug: Etarfolatide (EC20)
Normalized name: Etarfolatide
DrugBank: Etarfolatide (DB11810)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00747006
Drug: TI Inhalation Powder and Humalog (Amendment 1)
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
Study: NCT00747006
Drug: TI Inhalation Powder (original protocol)
Normalized name: insulin human, rDNA origin Inhalation Powder [Exubera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
Study: NCT01534546
Drug: Oxaliplatin capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
Study: NCT01534546
Drug: Oxaliplatin S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
Study: NCT02307396
Drug: bromperidol
Normalized name: bromperidol
DrugBank: Bromperidol (DB12401)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02307396
Drug: Flupentixole
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01462175
Drug: RO5503781
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01475266
Drug: EO9 (Apaziquone)
Normalized name: Apaziquone
DrugBank: Apaziquone (DB12593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Study: NCT01475266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
Study: NCT03406169
Drug: Sildenafil 25 MG Oral Tablet
Normalized name: sildenafil 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day dosing
Study: NCT02139241
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline as bolus before induction of general anesthesia
Study: NCT02310581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study: NCT00336505
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally